- Finland
- /
- Medical Equipment
- /
- HLSE:REG1V
Should You Be Tempted To Sell Revenio Group Oyj (HEL:REG1V) Because Of Its P/E Ratio?
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll show how you can use Revenio Group Oyj's (HEL:REG1V) P/E ratio to inform your assessment of the investment opportunity. Based on the last twelve months, Revenio Group Oyj's P/E ratio is 42.79. That means that at current prices, buyers pay €42.79 for every €1 in trailing yearly profits.
View our latest analysis for Revenio Group Oyj
How Do You Calculate A P/E Ratio?
The formula for price to earnings is:
Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)
Or for Revenio Group Oyj:
P/E of 42.79 = €13.72 ÷ €0.32 (Based on the trailing twelve months to September 2018.)
Is A High P/E Ratio Good?
A higher P/E ratio implies that investors pay a higher price for the earning power of the business. That is not a good or a bad thing per se, but a high P/E does imply buyers are optimistic about the future.
How Growth Rates Impact P/E Ratios
P/E ratios primarily reflect market expectations around earnings growth rates. That's because companies that grow earnings per share quickly will rapidly increase the 'E' in the equation. That means unless the share price increases, the P/E will reduce in a few years. Then, a lower P/E should attract more buyers, pushing the share price up.
Revenio Group Oyj's earnings per share grew by -7.8% in the last twelve months. And its annual EPS growth rate over 5 years is 19%.
How Does Revenio Group Oyj's P/E Ratio Compare To Its Peers?
We can get an indication of market expectations by looking at the P/E ratio. You can see in the image below that the average P/E (27.7) for companies in the medical equipment industry is lower than Revenio Group Oyj's P/E.

Its relatively high P/E ratio indicates that Revenio Group Oyj shareholders think it will perform better than other companies in its industry classification. The market is optimistic about the future, but that doesn't guarantee future growth. So further research is always essential. I often monitor director buying and selling.
A Limitation: P/E Ratios Ignore Debt and Cash In The Bank
Don't forget that the P/E ratio considers market capitalization. That means it doesn't take debt or cash into account. Theoretically, a business can improve its earnings (and produce a lower P/E in the future), by taking on debt (or spending its remaining cash).
Such expenditure might be good or bad, in the long term, but the point here is that the balance sheet is not reflected by this ratio.
How Does Revenio Group Oyj's Debt Impact Its P/E Ratio?
Revenio Group Oyj has net cash of €7.4m. That should lead to a higher P/E than if it did have debt, because its strong balance sheets gives it more options.
The Bottom Line On Revenio Group Oyj's P/E Ratio
Revenio Group Oyj has a P/E of 42.8. That's higher than the average in the FI market, which is 17.3. EPS was up modestly better over the last twelve months. And the healthy balance sheet means the company can sustain growth while the P/E suggests shareholders think it will.
When the market is wrong about a stock, it gives savvy investors an opportunity. If the reality for a company is better than it expects, you can make money by buying and holding for the long term. So this freereport on the analyst consensus forecasts could help you make a master move on this stock.
Of course you might be able to find a better stock than Revenio Group Oyj. So you may wish to see this freecollection of other companies that have grown earnings strongly.
To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.
Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
About HLSE:REG1V
Revenio Group Oyj
Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally.
Flawless balance sheet with reasonable growth potential.
Market Insights
Community Narratives
